Invivyd (IVVD) News Today

Invivyd, Inc. (NASDAQ:IVVD) shares have risen as the company secured U.S. FDA clearance for its VYD2311 program and attracted multiple bullish analyst actions, including new coverage and higher price targets.

• Positive Sentiment: U.S. FDA cleared Invivyd’s IND application and provided feedback on its pivotal VYD2311 clinical program to prevent COVID-19.Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
• Positive Sentiment: Cantor Fitzgerald initiated coverage of IVVD with an “overweight” rating and $10.00 price target, implying over 600% upside.Invivyd (NASDAQ:IVVD) Now Covered by Cantor Fitzgerald
• Positive Sentiment: D. Boral Capital maintained its “buy” recommendation on IVVD shares.D. Boral Capital Maintains Invivyd (IVVD) Buy Recommendation
• Positive Sentiment: D. Boral Capital raised its price target on IVVD from $1.00 to $2.00, reflecting a 40.8% upside from the prior close.D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00
• Positive Sentiment: Analysts at six brokerages rate IVVD an average “moderate buy,” with four buy ratings and one sell rating on record.Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts
• Neutral Sentiment: Five analysts shared insights on IVVD’s clinical and financial outlook without changing consensus ratings significantly.5 Analysts Have This To Say About Invivyd